These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33466377)

  • 1. A Case of Phage Therapy against Pandrug-Resistant
    Lebeaux D; Merabishvili M; Caudron E; Lannoy D; Van Simaey L; Duyvejonck H; Guillemain R; Thumerelle C; Podglajen I; Compain F; Kassis N; Mainardi JL; Wittmann J; Rohde C; Pirnay JP; Dufour N; Vermeulen S; Gansemans Y; Van Nieuwerburgh F; Vaneechoutte M
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33466377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report.
    Hoyle N; Zhvaniya P; Balarjishvili N; Bolkvadze D; Nadareishvili L; Nizharadze D; Wittmann J; Rohde C; Kutateladze M
    Res Microbiol; 2018 Nov; 169(9):540-542. PubMed ID: 29777836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
    Lobo LJ; Tulu Z; Aris RM; Noone PG
    Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis.
    Talbot NP; Flight WG
    Paediatr Respir Rev; 2016 Aug; 20 Suppl():27-9. PubMed ID: 27374622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
    De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M
    J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis.
    Firmida MC; Pereira RH; Silva EA; Marques EA; Lopes AJ
    Braz J Med Biol Res; 2016; 49(4):e5097. PubMed ID: 26909788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achromobacter xylosoxidans infection in an adult cystic fibrosis unit in Madrid.
    Llorca Otero L; Girón Moreno R; Buendía Moreno B; Valenzuela C; Guiu Martínez A; Alarcón Cavero T
    Enferm Infecc Microbiol Clin; 2016 Mar; 34(3):184-7. PubMed ID: 26139304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.
    Dupont C; Jumas-Bilak E; Doisy C; Aujoulat F; Chiron R; Marchandin H
    Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217850
    [No Abstract]   [Full Text] [Related]  

  • 9. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.
    Amoureux L; Bador J; Siebor E; Taillefumier N; Fanton A; Neuwirth C
    J Cyst Fibros; 2013 Mar; 12(2):170-6. PubMed ID: 22944724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates.
    Amoureux L; Bador J; Bounoua Zouak F; Chapuis A; de Curraize C; Neuwirth C
    J Cyst Fibros; 2016 Jul; 15(4):486-94. PubMed ID: 26778615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.
    Warner NC; Bartelt LA; Lachiewicz AM; Tompkins KM; Miller MB; Alby K; Jones MB; Carr AL; Alexander J; Gainey AB; Daniels R; Burch AK; Brown DE; Brownstein MJ; Cheema F; Linder KE; Shields RK; Longworth S; van Duin D
    Clin Infect Dis; 2021 Oct; 73(7):e1754-e1757. PubMed ID: 33313656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137.
    Amoureux L; Sauge J; Sarret B; Lhoumeau M; Bajard A; Tetu J; Bador J; Neuwirth C;
    J Cyst Fibros; 2019 Nov; 18(6):804-807. PubMed ID: 31104975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic characterization of
    Veschetti L; Sandri A; Patuzzo C; Melotti P; Malerba G; Lleo MM
    Microb Genom; 2021 Jul; 7(7):. PubMed ID: 34292148
    [No Abstract]   [Full Text] [Related]  

  • 14. Achromobacter xylosoxidans induced bronchiolitis obliterans in cystic fibrosis.
    De Baets F; Schelstraete P; Haerynck F; Van Biervliet S; De Bruyne R; Franckx H; Van Daele S
    Pediatr Pulmonol; 2014 Apr; 49(4):414-6. PubMed ID: 24039244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sepsis Caused by Achromobacter Xylosoxidans in a Child with Cystic Fibrosis and Severe Lung Disease.
    Stobbelaar K; Van Hoorenbeeck K; Lequesne M; De Dooy J; Ho E; Vlieghe E; Ieven M; Verhulst S
    Am J Case Rep; 2016 Aug; 17():562-6. PubMed ID: 27498677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.
    Hansen CR; Pressler T; Nielsen KG; Jensen PØ; Bjarnsholt T; Høiby N
    J Cyst Fibros; 2010 Jan; 9(1):51-8. PubMed ID: 19939747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the
    Le Goff M; Vastel M; Lebrun R; Mansuelle P; Diarra A; Grandjean T; Triponney P; Imbert G; Gosset P; Dessein R; Garnier F; Durand E
    Front Cell Infect Microbiol; 2022; 12():859181. PubMed ID: 35782124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral Pneumonia in a Patient with Chronic Bronchiectasis Caused by Achromobacter xylosoxidans Subspecies denitrificans.
    Stepman G; Dabb K; Khan IA; Young JT; Frunzi J
    Cureus; 2020 Mar; 12(3):e7381. PubMed ID: 32328391
    [No Abstract]   [Full Text] [Related]  

  • 19. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment.
    Ridderberg W; Bendstrup KE; Olesen HV; Jensen-Fangel S; Nørskov-Lauritsen N
    J Cyst Fibros; 2011 Dec; 10(6):466-9. PubMed ID: 21835703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature.
    Cools P; Ho E; Vranckx K; Schelstraete P; Wurth B; Franckx H; Ieven G; Van Simaey L; Van Daele S; Verhulst S; De Baets F; Vaneechoutte M
    BMC Microbiol; 2016 Jun; 16(1):122. PubMed ID: 27342812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.